Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esmolol versus remifentanil during maxillofacial surgery and recovery
RBR-9hdghd3Phase 4Not yet recruiting
- Sponsor
- Ebserh
- Start
- Mar 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial comparing Remifentanil infusion with Esmolol infusion (2 arms). Primary endpoints: Hemodynamic efficacy, Safety and 1 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
esmololremifentanil
Beyond the preview
Go deeper on RBR-9hdghd3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-9hdghd3.